<SEC-DOCUMENT>0001193125-18-296050.txt : 20181009
<SEC-HEADER>0001193125-18-296050.hdr.sgml : 20181009
<ACCEPTANCE-DATETIME>20181009170501
ACCESSION NUMBER:		0001193125-18-296050
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20181009
FILED AS OF DATE:		20181009
DATE AS OF CHANGE:		20181009

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NuCana plc
		CENTRAL INDEX KEY:			0001709626
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38215
		FILM NUMBER:		181114290

	BUSINESS ADDRESS:	
		STREET 1:		3 LOCHSIDE WAY
		CITY:			EDINBURGH
		STATE:			X0
		ZIP:			EH12 9DT
		BUSINESS PHONE:		44-0-131-248-3660

	MAIL ADDRESS:	
		STREET 1:		3 LOCHSIDE WAY
		CITY:			EDINBURGH
		STATE:			X0
		ZIP:			EH12 9DT

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NuCana BioMed Ltd
		DATE OF NAME CHANGE:	20170619
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d636792d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B><FONT
STYLE="white-space:nowrap">FORM&nbsp;6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">RULE&nbsp;13a-16&nbsp;OR&nbsp;15d-16</FONT></FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>OF THE
SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Commission <FONT STYLE="white-space:nowrap">File&nbsp;No.&nbsp;001-38215)</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>NUCANA PLC </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation
of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>3 Lochside
Way </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Edinburgh EH12 9DT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>United Kingdom </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address
of registrant&#146;s principal executive office) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether
the registrant files or will file annual reports under <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">cover&nbsp;Form&nbsp;20-F&nbsp;or&nbsp;Form&nbsp;40-F.</FONT></FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Form&nbsp;20-F&nbsp;&nbsp;&#9746;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
Form&nbsp;40-F&nbsp;&nbsp;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting
<FONT STYLE="white-space:nowrap">the&nbsp;Form&nbsp;6-K&nbsp;in</FONT> paper as permitted by <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-T&nbsp;Rule&nbsp;101&nbsp;(b)&nbsp;(1):&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting <FONT STYLE="white-space:nowrap">the&nbsp;Form&nbsp;6-K&nbsp;in</FONT> paper as permitted by <FONT
STYLE="white-space:nowrap">Regulation&nbsp;S-T&nbsp;Rule&nbsp;101&nbsp;(b)&nbsp;(7):&nbsp;&nbsp;&#9744;</FONT> </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Other Events </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&nbsp;9, 2018, NuCana plc (the &#147;Company&#148;) issued a press release announcing that the Company is to present new data from its Acelarin <FONT
STYLE="white-space:nowrap">(NUC-1031)</FONT> and <FONT STYLE="white-space:nowrap">NUC-3373</FONT> programs at the European Society for Medical Oncology (ESMO) 2018 Congress. The press release is attached as Exhibit 99.1 hereto and is incorporated by
reference herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information in the attached Exhibit 99.1 is being furnished and shall not be deemed &#147;filed&#148; for the purposes of
Section&nbsp;18 of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the
Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><U>Exhibits </U></B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="94%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d636792dex991.htm">Press Release dated October&nbsp;9, 2018 </A></TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SIGNATURES </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="12%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>NuCana plc</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Donald Munoz</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Donald Munoz</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief&nbsp;Financial&nbsp;Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: October&nbsp;9, 2018 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d636792dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NuCana to Present New Data from its ProTide Portfolio at the European Society for </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Medical Oncology (ESMO) 2018 Congress </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Edinburgh, United Kingdom, October&nbsp;9, 2018 (GLOBE NEWSWIRE) &#150; NuCana plc<I> </I>(NASDAQ:NCNA), a clinical-stage biopharmaceutical company focused on
significantly improving treatment outcomes for patients with cancer, today announced that investigators will present new data from the Acelarin <FONT STYLE="white-space:nowrap">(NUC-1031)</FONT> and <FONT STYLE="white-space:nowrap">NUC-3373</FONT>
programs at the ESMO 2018 Congress to be held October <FONT STYLE="white-space:nowrap">19-23,</FONT> 2018, in Munich, Germany. These data include the latest results from the <FONT STYLE="white-space:nowrap">ABC-08</FONT> Phase Ib front-line study of
Acelarin plus cisplatin in advanced biliary tract cancer, as well as a recruitment update from the Acelarate Phase III front-line study of Acelarin in pancreatic cancer. In addition, results from the NuTide:301 Phase I study of <FONT
STYLE="white-space:nowrap">NUC-3373</FONT> in advanced solid tumors will be presented. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Hugh S. Griffith, NuCana&#146;s Chief Executive Officer, said:
&#147;We are excited about sharing these latest data at ESMO and the potential of our pipeline of innovative ProTides to transform the treatment of patients with cancer.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Details of NuCana&#146;s poster presentations are as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Poster Presentation Session Date</B><B></B><B>&nbsp;&amp; Time: </B>October&nbsp;21, 2018, 12:45pm CEST<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B>&nbsp;A new ProTide, <FONT STYLE="white-space:nowrap">NUC-1031,</FONT> combined with cisplatin for the first-line treatment of advanced biliary
tract cancer <FONT STYLE="white-space:nowrap">(ABC-08)</FONT><B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation Number:</B><B></B>&nbsp;758P<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Title:</B>&nbsp;Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal&nbsp;&amp;
<FONT STYLE="white-space:nowrap">non-colorectal,</FONT> Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology&nbsp;&amp; pathology<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location:</B>&nbsp;Hall A3, Poster Area Networking Hub<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presenter:</B><B></B>&nbsp;Dr.&nbsp;Mairead McNamara </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Poster</B><B>&nbsp;Presentation Session Date</B><B></B><B>&nbsp;&amp; Time:</B>&nbsp;October 21, 2018, 12:45pm CEST<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B>&nbsp;ACELARATE &#150; A randomised Phase III, open label, clinical study comparing <FONT STYLE="white-space:nowrap">NUC-1031</FONT> with
gemcitabine in patients with metastatic pancreatic carcinoma<B> </B> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation Number:</B>&nbsp;788TiP<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session Title:</B>&nbsp;Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal&nbsp;&amp;
<FONT STYLE="white-space:nowrap">non-colorectal,</FONT> Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology&nbsp;&amp; pathology<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location:</B>&nbsp;Hall A3 - Poster Area Networking Hub<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presenter:</B><B></B>&nbsp;Professor Daniel Palmer </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Poster</B><B>&nbsp;Presentation Session Date</B><B></B><B>&nbsp;&amp; Time:</B>&nbsp;October 22, 2018,
12:45pm CEST<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title:</B>&nbsp;A Phase I <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT>
dose-escalation and expansion study to evaluate the safety and tolerability of <FONT STYLE="white-space:nowrap">NUC-3373</FONT> in patients with locally advanced, unresectable or metastatic solid malignancies </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presentation Number:</B>&nbsp;442TiP<B> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Session
Title:</B>&nbsp;Breast cancer - early stage, locally advanced&nbsp;&amp; metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours&#151;prostate&nbsp;&amp; <FONT STYLE="white-space:nowrap">non-prostate,</FONT> Palliative care,
Psycho-oncology, Public health policy, Sarcoma, Supportive care </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Location:</B>&nbsp;Hall A3 - Poster Area Networking Hub<B> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Presenter:</B><B></B>&nbsp;Professor Sarah Blagden </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Abstracts
and full session details can be found at<B>&nbsp;www.esmo.org</B> </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>About NuCana plc </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>NuCana<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> is a clinical-stage biopharmaceutical company focused on significantly improving treatment
outcomes for cancer patients by applying our ProTide<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> technology to transform some of the most widely prescribed chemotherapy agents, nucleoside analogs, into more effective and safer
medicines. While these conventional agents remain part of the standard of care for the treatment of many solid tumors, their efficacy is limited by cancer cell resistance mechanisms and they are often poorly tolerated. Utilizing our proprietary
technology, we are developing new medicines, ProTides, designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Our most advanced ProTide candidates, Acelarin<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> <FONT STYLE="white-space:nowrap">(NUC-1031)</FONT>
and <FONT STYLE="white-space:nowrap">NUC-3373,</FONT> are new chemical entities derived from the nucleoside analogs gemcitabine and <FONT STYLE="white-space:nowrap">5-fluorouracil,</FONT> respectively, two widely used chemotherapy agents. Acelarin
is currently being evaluated in three clinical studies, including a Phase Ib study for patients with biliary tract cancer, a Phase II study for patients with ovarian cancer and a Phase III study for patients with pancreatic cancer. <FONT
STYLE="white-space:nowrap">NUC-3373</FONT> is currently in a Phase I study for the potential treatment of a wide range of advanced solid tumors. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>For more information, please visit: www.nucana.com </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Forward-Looking Statements </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release may
contain &#147;forward -looking&#148; statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are based on the beliefs and assumptions and on information currently available to management of NuCana plc (the
&#147;Company&#148;). All statements other than statements of historical fact contained in this press release are forward-looking statements, including our planned and ongoing clinical studies for the Company&#146;s product candidates, including
Acelarin, <FONT STYLE="white-space:nowrap">NUC-3373</FONT> and <FONT STYLE="white-space:nowrap">NUC-7738;</FONT> the initiation, enrollment, timing, progress, release of data from and results of those planned and ongoing clinical studies; and the
utility of prior preclinical and clinical data in </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
determining future clinical results. In some cases, you can identify forward-looking statements by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148;
&#147;plans,&#148; &#147;anticipates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential&#148; or &#147;continue&#148; or the negative of these terms or other comparable terminology. Forward-looking statements
involve known and unknown risks, uncertainties and other factors that may cause the Company&#146;s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by
the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the &#147;Risk Factors&#148; section of our Annual Report on Form <FONT STYLE="white-space:nowrap">20-F</FONT>
for the year ended December&nbsp;31, 2017 filed with the Securities and Exchange Commission (&#147;SEC&#148;) on March&nbsp;22, 2018, and subsequent reports that we file with the SEC. Forward-looking statements represent the Company&#146;s beliefs
and assumptions only as of the date of this press release. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, levels of activity, performance or
achievements. Except as required by law, the Company assumes no obligation to publicly update any <FONT STYLE="white-space:nowrap">forward-looking</FONT> statements for any reason after the date of this press release to conform any of the
forward-looking statements to actual results or to changes in its expectations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>For more information, please contact: </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>NuCana plc </I></B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>&nbsp;&nbsp;&nbsp;&nbsp;Hugh S.
Griffith&nbsp;&nbsp;&nbsp;&nbsp;Chief Executive Officer&nbsp;&nbsp;&nbsp;&nbsp;T: +44 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">131-357-1111&nbsp;&nbsp;&nbsp;&nbsp;E:</FONT></FONT> info@nucana.com </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I></I><B><I>Westwicke Partners</I></B><I> </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;<I>Chris Brinzey&nbsp;&nbsp;&nbsp;&nbsp;T: +1
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">339-970-2843&nbsp;&nbsp;&nbsp;&nbsp;E:</FONT></FONT> chris.brinzey@westwicke.com</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>RooneyPartners </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;Marion
Janic&nbsp;&nbsp;&nbsp;&nbsp;T: +1 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">212-223-4017&nbsp;&nbsp;&nbsp;&nbsp;E:</FONT></FONT> mjanic@rooneyco.com </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
